Zobrazeno 1 - 10
of 276
pro vyhledávání: '"Leo, Luznik"'
Autor:
Sergio Rutella, Jayakumar Vadakekolathu, Francesco Mazziotta, Stephen Reeder, Tung-On Yau, Rupkatha Mukhopadhyay, Benjamin Dickins, Heidi Altmann, Michael Kramer, Hanna A. Knaus, Bruce R. Blazar, Vedran Radojcic, Joshua F. Zeidner, Andrea Arruda, Bofei Wang, Hussein A. Abbas, Mark D. Minden, Sarah K. Tasian, Martin Bornhäuser, Ivana Gojo, Leo Luznik
Publikováno v:
The Journal of Clinical Investigation, Vol 132, Iss 21 (2022)
Background Immune exhaustion and senescence are dominant dysfunctional states of effector T cells and major hurdles for the success of cancer immunotherapy. In the current study, we characterized how acute myeloid leukemia (AML) promotes the generati
Externí odkaz:
https://doaj.org/article/9b9ef0d762ff4c06a07a3be5dd99fa73
Autor:
Yiouli P. Ktena, Michael A. Koldobskiy, Michael I. Barbato, Han-Hsuan Fu, Leo Luznik, Nicolas J. Llosa, Azeb Haile, Orly R. Klein, Chen Liu, Christopher J. Gamper, Kenneth R. Cooke
Publikováno v:
The Journal of Clinical Investigation, Vol 132, Iss 13 (2022)
DNA methyltransferase 3a (DNMT3a) is an important part of the epigenetic machinery that stabilizes patterns of activated T cell responses. We hypothesized that donor T cell DNMT3a regulates alloreactivity after allogeneic blood and marrow transplanta
Externí odkaz:
https://doaj.org/article/c4e9109a86424b8ea4684ab6e13f66fe
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
With advances in allogeneic hematopoietic stem cell transplant (allo-HCT), disease relapse has replaced transplant-related mortality as the primary cause of treatment failure for patients with acute myeloid leukemia (AML). The efficacy of allo-HCT in
Externí odkaz:
https://doaj.org/article/c6a972e604a941279a7e909c882bd98a
Autor:
Mohamad A. Meybodi, Wenhao Cao, Leo Luznik, Asad Bashey, Xu Zhang, Rizwan Romee, Wael Saber, Mehdi Hamadani, Daniel J. Weisdorf, Haitao Chu, Armin Rashidi
Publikováno v:
Blood Advances, Vol 3, Iss 17, Pp 2581-2585 (2019)
Abstract: HLA haploidentical hematopoietic cell transplantation (haplo-HCT) using posttransplantation cyclophosphamide (PT-Cy) is an alternative strategy when a matched sibling donor (MSD) is not available. We performed a systematic review and meta-a
Externí odkaz:
https://doaj.org/article/5e76d957cb714c6daf90c417b5b4538d
Autor:
Philip H. Imus, Hua-Ling Tsai, Leo Luznik, Ephraim J. Fuchs, Carol Ann Huff, Douglas E. Gladstone, Patrick Lowery, Richard F. Ambinder, Ivan M. Borrello, Lode J. Swinnen, Nina Wagner-Johnston, Christian B. Gocke, Syed Abbas Ali, F.Javier Bolaños-Meade, Ravi Varadhan, Richard J. Jones
Publikováno v:
Blood Advances, Vol 3, Iss 17, Pp 2608-2616 (2019)
Abstract: Hematologic malignancies in older people are unlikely to be cured with chemotherapy alone. Advances in allogeneic blood or marrow transplantation (alloBMT), especially nonmyeloablative (NMA) conditioning and the use of haploidentical donors
Externí odkaz:
https://doaj.org/article/197de5e065234acea249f8b75efa3cfa
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Following allogeneic blood and marrow transplantation (BMT), graft-versus-host disease (GvHD) continues to represent a significant cause of treatment failure, despite the routine use of conventional, mainly calcineurin inhibitor-based prophylaxis. Re
Externí odkaz:
https://doaj.org/article/100d22a9d67d4ab8a0e8d3dc7b19b766
Autor:
Bhagirathbhai Dholaria, Bipin N. Savani, Myriam Labopin, Leo Luznik, Annalisa Ruggeri, Stephan Mielke, Monzr M. Al Malki, Piyanuch Kongtim, Ephraim Fuchs, Xiao-Jun Huang, Franco Locatelli, Franco Aversa, Luca Castagna, Andrea Bacigalupo, Massimo Martelli, Didier Blaise, Patrick Ben Soussan, Yolande Arnault, Rupert Handgretinger, Denis-Claude Roy, Paul O’Donnell, Asad Bashey, Scott Solomon, Rizwan Romee, Philippe Lewalle, Jorge Gayoso, Michael Maschan, Hillard M. Lazarus, Karen Ballen, Sebastian Giebel, Frederic Baron, Fabio Ciceri, Jordi Esteve, Norbert-Claude Gorin, Alexandros Spyridonidis, Christoph Schmid, Stefan O. Ciurea, Arnon Nagler, Mohamad Mohty
Publikováno v:
Haematologica, Vol 105, Iss 1 (2020)
Donor lymphocyte infusion has been used in the management of relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. It can eradicate minimal residual disease or be used to rescue a hematologic relapse, being able to in
Externí odkaz:
https://doaj.org/article/c78e0176ca4848d983f2814ad0142a70
Autor:
Courtney D. Fitzhugh, Matthew M. Hsieh, Tiffani Taylor, Wynona Coles, Katherine Roskom, Delon Wilson, Elizabeth Wright, Neal Jeffries, Christopher J. Gamper, Jonathan Powell, Leo Luznik, John F. Tisdale
Publikováno v:
Blood Advances, Vol 1, Iss 11, Pp 652-661 (2017)
Abstract: Peripheral blood stem cell transplantation (PBSCT) offers a curative option for sickle cell disease (SCD). Although HLA-matched sibling transplantation is promising, the vast majority of patients lack such a donor. We sought to develop a no
Externí odkaz:
https://doaj.org/article/a96a5f8323f4493ab06d444945ba818d
Autor:
Yvette L. Kasamon, Richard F. Ambinder, Ephraim J. Fuchs, Marianna Zahurak, Gary L. Rosner, Javier Bolaños-Meade, Mark J. Levis, Douglas E. Gladstone, Carol Ann Huff, Lode J. Swinnen, William H. Matsui, Ivan Borrello, Robert A. Brodsky, Richard J. Jones, Leo Luznik
Publikováno v:
Blood Advances, Vol 1, Iss 4, Pp 288-292 (2017)
Abstract: Allogeneic blood or marrow transplantation (BMT) candidates may lack HLA-matched, related haploidentical, and unrelated umbilical cord options. Barriers to partially HLA-mismatched, unrelated donor (mMUD) BMT include excess graft-versus-hos
Externí odkaz:
https://doaj.org/article/af2ec2c8d00b48949c2586a19a5e7f02
Autor:
Amy DeZern, Marianna L Zahurak, Heather J Symons, Kenneth R. Cooke, Carol Ann Huff, Tania Jain, Lode J Swinnen, Philip Hollingsworth Imus, Nina D. Wagner-Johnston, Richard F Ambinder, Mark J. Levis, Leo Luznik, Javier Bolaños-Meade, Ephraim J Fuchs, Richard J Jones, Robert A. Brodsky
Publikováno v:
Blood Journal.
Severe aplastic anemia (SAA) is a marrow failure disorder with high morbidity and mortality. It is treated with bone marrow transplantation (BMT) for those with fully matched donors or immunosuppressive therapy (IST) for those who lack such a donor,